`
`(Reference Data of Financial Statements for the 2Q of Fiscal 2015)
`
`November 6, 2015
`
`KAKEN PHARMACEUTICAL CO., LTD.
`
` Corporate Communications
` Tel:
` +81-(0)3-5977-5002
` Fax:
` +81-(0)3-5977-5131
` Email:
` koho@kaken.co.jp
`
`ACRUX DDS PTY LTD. et al.
`
`EXHIBIT 1647
`
`IPR Petition for
`
`U.S. Patent No. 7,214,506
`
`Page 1 of 5
`
`
`
`1. Summary of Consolidated Financial Statements for the Second Quarter of Fiscal 2015
`
`( Figures less than one million yen have been omitted)
`
`FY2014
`2nd Q
`
`FY2014
`
`FY2015
`2nd Q
`
`Y o Y increase (decrease)
`
`Yen
`
`%
`
`FY2015
`Forecasts
`
`Net sales
`
`Operating income
`
` Ratio of net sales
`
`44,232
`
`8,806
`
`19.9%
`
`93,889
`
`20,631
`
`54,973
`
`18,443
`
`22.0%
`
`33.6%
`
`10,740
`
`124.3% 107,900
`
`9,636
`
`209.4%
`
`32,200
`
`29.8%
`
`Y o Y increase (decrease)
`
`Yen
`
`14,011
`
`11,569
`
`%
`
`114.9%
`
`156.1%
`
`Ordinary income
`
`8,677
`
`20,394
`
`18,573
`
`9,896
`
`214.1%
`
`32,400
`
`12,006
`
`158.9%
`
` Ratio of net sales
`
`19.6%
`
`21.7%
`
`33.8%
`
`30.0%
`
`Net income
`
`5,639
`
`12,122
`
`12,483
`
`6,844
`
`221.4%
`
`19,200
`
`7,078
`
`158.4%
`
` Ratio of net sales
`
`12.7%
`
`12.9%
`
`22.7%
`
`Per share profit (Yen)
`
`134.56
`
`290.90
`
`301.39
`
`17.8%
`
`463.66
`
`Note: Kaken has conducted a consolidation of common share at rate of one share for every two shares with effective date of October 1, 2015.
` Per shar profit has been calculated as if this consolidation of shares was conducted at the bigining of previous fiscal year.
`
`Comprehensive income
`
`6,603
`
`16,607
`
`11,308
`
`4,704
`
`171.2%
`
`Capital investment
`
`1,156
`
`2,806
`
`1,529
`
`372
`
`132.2%
`
`3,200
`
`394
`
`114.0%
`
`R&D expenses
`
`3,374
`
`7,615
`
`2,965
`
`(408)
`
`87.9%
`
`8,300
`
`685
`
`109.0%
`
`Depreciation and amortization
`
`1,175
`
`2,400
`
`1,039
`
`(135)
`
`88.4%
`
`2,200
`
`(200)
`
`91.7%
`
`Employee number
`
`1,541
`
`1,503
`
`1,482
`
`(59)
`
`2. Breakdown of Consolidated Net Sales by Segment
`
`( Figures less than one million yen have been omitted)
`
`FY2014
`2nd Q
`
`FY2014
`
`FY2015
`2nd Q
`
`Y o Y increase (decrease)
`
`Yen
`
`%
`
`43,005
`
`91,458
`
`53,794
`
`10,788
`
`125.1%
`
`Pharmaceuticals,
`medical devices &
`agrochemicals
`
`Real estate
`
`1,226
`
`2,431
`
`1,178
`
`(47)
`
`96.1%
`
`Total
`
`44,232
`
`93,889
`
`54,973
`
`10,740
`
`124.3%
`
`KAKEN PHARMACEUTICAL CO., LTD.
`
`Page 2 of 5
`
`
`
`3. Summary of Consolidated Balance Sheets
`
`As of
`September 30,
`2014
`
`Ratio
`
`( Figures less than one million yen have been omitted)
`As of
`Y o Y
`March 31,
`increase
`2015
`(decrease)
`
`Ratio
`
`As of
`September 30,
`2015
`
`Ratio
`
`Assets
`
`106,193
`
`100.0%
`
`115,135
`
`100.0%
`
`124,299
`
`100.0%
`
`9,164
`
`54.6%
`
`69,016
`
`59.9%
`
`79,022
`
`63.6%
`
`10,005
`
` Current assets
`
` Noncurrent assets
`
`Liabilities
`
` Current liabilities
`
` Noncurrent liabilities
`
`58,027
`
`48,166
`
`36,781
`
`27,598
`
`9,182
`
`45.4%
`
`46,118
`
`40.1%
`
`45,277
`
`34.6%
`
`38,035
`
`33.0%
`
`38,714
`
`26.0%
`
`30,369
`
`26.4%
`
`31,727
`
`8.6%
`
`7,665
`
`6.7%
`
`6,986
`
`Net assets
`
`69,411
`
`65.4%
`
`77,100
`
`67.0%
`
`85,585
`
`22.5%
`
`23,853
`
`20.7%
`
`23,853
`
`36.4%
`
`31.1%
`
`25.5%
`
`5.6%
`
`68.9%
`
`19.2%
`
`(841)
`
`679
`
`1,358
`
`(679)
`
`8,485
`
`-
`
` Capital stock
`
` Capital surplus
`
` Retained earnings
`
`23,853
`
`11,407
`
`48,686
`
`10.7%
`
`11,406
`
`9.9%
`
`11,407
`
`9.2%
`
`0
`
`45.8%
`
`52,932
`
`46.0%
`
`62,765
`
`50.5%
`
`9,832
`
` Treasury stock
`
`(16,021)
`
`(15.1%)
`
`(16,098)
`
`(14.0%)
`
`(16,271)
`
`(13.1%)
`
`(172)
`
`Valuation difference on
`available-for-sale securities
`
`Remeasurements of defined
`benefit plans
`
`3,040
`
`2.9%
`
`5,478
`
`4.8%
`
`4,188
`
`3.4%
`
`(1,289)
`
`(1,554)
`
`(1.5%)
`
`(472)
`
`(0.4%)
`
`(357)
`
`(0.3%)
`
`114
`
`4. Summary of Consolidated Statements of Cash Flows
`
`( Figures less than one million yen have been omitted)
`Y o Y
`increase
`(decrease)
`
`FY2014
`2Q
`
`FY2014
`
`FY2015
`2nd Q
`
`Net cash provided by (used in) operating activities
`
`3,175
`
`14,737
`
`10,551
`
`Net cash provided by (used in) investing activities
`
`(795)
`
`473
`
`(1,754)
`
`7,375
`
`(959)
`
`Net cash provided by (used in) financing activities
`
`(5,586)
`
`(7,900)
`
`(2,821)
`
`2,764
`
`Cash and cash equivalents at end of period
`
`14,251
`
`24,767
`
`30,742
`
`16,491
`
`KAKEN PHARMACEUTICAL CO., LTD.
`
`Page 3 of 5
`
`
`
`5. Summary of Non-consolidated Financial Statements for the Second Quarter of Fiscal 2015
`
`( Figures less than one million yen have been omitted)
`
`Net sales
`
`Operating income
`
` Ratio of net sales
`
`FY2014
`2Q
`
`FY2014
`
`FY2015
`2Q
`
`43,349
`
`8,496
`
`19.6%
`
`91,951
`
`19,994
`
`53,851
`
`18,119
`
`21.7%
`
`33.6%
`
`Y o Y increase(decrease) FY2015
`Forecasts
`
`Yen
`
`%
`
`10,502
`
`124.2% 105,700
`
`9,623
`
`213.3%
`
`31,500
`
`29.8%
`
`Y o Y increase(decrease)
`
`Yen
`
`13,749
`
`11,506
`
`%
`
`115.0%
`
`157.5%
`
`Ordinary income
`
`8,411
`
`19,845
`
`18,277
`
`9,866
`
`217.3%
`
`31,800
`
`11,955
`
`160.2%
`
` Ratio of net sales
`
`19.4%
`
`21.6%
`
`33.9%
`
`30.1%
`
`Net income
`
`5,481
`
`11,777
`
`12,295
`
`6,813
`
`224.3%
`
`16,900
`
`5,123
`
`143.5%
`
` Ratio of net sales
`
`12.6%
`
`12.8%
`
`22.8%
`
`16.0%
`
`Capital investment
`
`1,137
`
`2,777
`
`1,508
`
`370
`
`132.5%
`
`3,100
`
`323
`
`111.6%
`
`R&D expenses
`
`3,374
`
`7,615
`
`2,965
`
`(408)
`
`87.9%
`
`8,300
`
`685
`
`109.0%
`
`Depreciation and amortization
`
`1,135
`
`2,319
`
`998
`
`(136)
`
`87.9%
`
`2,200
`
`(119)
`
`94.9%
`
`Export volume
`
` Pharmaceuticals
`
` Agrochemicals
`
`2,950
`
`1,998
`
`952
`
`7,220
`
`4,813
`
`2,407
`
`5,088
`
`4,231
`
`856
`
`2,138
`
`2,233
`
`172.5%
`
`211.7%
`
`(95)
`
`90.0%
`
`Employee number
`
`1,523
`
`1,493
`
`1,475
`
`(48)
`
`6. Breakdown of Non-consolidated Net Sales by Segment
`
`( Figures less than one million yen have been omitted)
`
`FY2014
`2Q
`
`FY2014
`
`FY2015
`2Q
`
`Y o Y increase(decrease) FY2015
`Forecasts
`
`Yen
`
`%
`
`
`
`Y o Y increase(decrease)Y o Y increase(decrease)
`
`Yen
`
`%
`
`Pharmaceuticals &
`medical devices
`
`Agrochemicals
`
`Renting real estate
`
`40,478
`
`84,444
`
`50,790
`
`10,311
`
`125.5%
`
`98,180
`
`13,736
`
`116.3%
`
`1,843
`
`1,027
`
`5,472
`
`2,034
`
`2,080
`
`981
`
`236
`
`(46)
`
`112.8%
`
`95.5%
`
`5,580
`
`1,940
`
`108
`
`(94)
`
`102.0%
`
`95.4%
`
`Total
`
`43,349
`
`91,951
`
`53,851
`
`10,502
`
`124.2% 105,700
`
`13,749
`
`115.0%
`
`KAKEN PHARMACEUTICAL CO., LTD.
`
`Page 4 of 5
`
`
`
`7. Breakdown of Sales by Main Pharmaceuticals and Medical Devices
`
`( Figures less than one million yen have been omitted)
`
`FY2014
`2Q
`
`FY2014
`
`FY2015
`2Q
`
`%
`
`FY2015
`Forecasts
`
`%
`
`15,600
`
`30,259
`
`15,659
`
`100.4%
`
`30,600
`
`101.1%
`
`1,430
`
`6,857
`
`9,804
`
`685.3%
`
`17,500
`
`255.2%
`
`5,309
`
`10,791
`
`5,641
`
`106.3%
`
`11,200
`
`103.8%
`
`2,143
`
`4,373
`
`2,237
`
`104.4%
`
`4,600
`
`105.2%
`
`1,730
`
`3,511
`
`1,816
`
`105.0%
`
`3,600
`
`102.5%
`
`Anti-osteoarthritis
`Artz
`
`Anti-nail fungus
`Clenafin
`
`Post-operative anti-adhesive
`Seprafilm
`
`Anti-hyperlipidemia
`Lipidil
`
`Wound healing agent
`Fiblast Spray
`
`Generic products
`
`6,054
`
`12,380
`
`6,584
`
`108.8%
`
`13,300
`
`107.4%
`
`Sales of Jublia*
`
`1,387
`
`3,318
`
`3,474
`
`250.4%
`
`6,000
`
`180.8%
`
`(*
`
`including sales of API and finished product, royalty revenue and
`milestone revenue)
`
`8. Development Status
`
`Code
`
`Indication
`
`Stage
`
`Remarks
`
`KCB-1D
`
`Periodontitis
`
`Filed
`
`bFGF
`
`KAG-308
`
`Ulcerative colitis
`
`PII
`
`Developed jointly with Asahi Glass Co., Ltd.;
`Oral-use prostaglandin analog
`
`BBI-4000
`
`Primary focal
`hyperhidrosis
`
`Preparing for PI
`
`Licensed from Brickell Biotech, Inc.;
`Topical anticholinergic
`
`SI-657
`
`Enthesopathy
`
`PIII
`
`Developed jointly with Seikagaku
`Corporation;
`Additional indication for ARTZ
`
`KAKEN PHARMACEUTICAL CO., LTD.
`
`Page 5 of 5
`
`